Pharmacopsychiatry 2022; 55(05): 274-275
DOI: 10.1055/a-1882-6802
Letter to the Editor

The Therapeutic Potential of Pimavanserin in the Treatment of Hallucinogen Induced Psychosis and Persistent Perceptual Symptoms

Mark A. Colijn


Publication History

Article published online:
11 July 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Cusick E, Gupta V. Pimavanserin. In: StatPearls. Treasure Island (FL). 2022
  • 2 Howland RH. Pimavanserin: An Inverse Agonist Antipsychotic Drug. J Psychosoc Nurs Ment Health Serv 2016; 54: 21-24
  • 3 Jalal B. The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug. Psychopharmacology (Berl) 2018; 235: 3083-3091
  • 4 Litjens RP, Brunt TM, Alderliefste GJ. et al. Hallucinogen persisting perception disorder and the serotonergic system: a comprehensive review including new MDMA-related clinical cases. Eur Neuropsychopharmacol 2014; 24: 1309-1323
  • 5 American Psychiatric A.. Diagnostic and Statistical Manual of Mental Disorders 2013;
  • 6 Martinotti G, Santacroce R, Pettorruso M. et al. Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives. Brain Sci 2018; 8
  • 7 Alcantara AG. Is there a role for the alpha2 antagonism in the exacerbation of hallucinogen-persisting perception disorder with risperidone?. J Clin Psychopharmacol 1998; 18: 487-488
  • 8 Lev-Ran S, Feingold D, Frenkel A. et al. Clinical characteristics of individuals with schizophrenia and hallucinogen persisting perception disorder: a preliminary investigation. J Dual Diagn 2014; 10: 79-83
  • 9 Lev-Ran S, Feingold D, Rudinski D. et al. Schizophrenia and hallucinogen persisting perception disorder: A clinical investigation. Am J Addict 2015; 24: 197-199
  • 10 Nutting S, Bruinsma T, Anderson M. et al. Psychotic and Still Tripping – Hallucinogen Persisting Perception Disorder and First Break Psychosis in an Adolescent. Int J Ment Health Addict 2020; 19: 2440-2442